Effects of saxagliptin on β ‐cell stimulation and insulin secretion in patients with type 2 diabetes
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aim: To study the effect of dipeptidyl peptidase‐4 (DPP‐4) inhibition with saxagliptin on β ‐cell function as reflected by the stimulated insulin secretion rate after an enteral glucose load in patients with type 2 diabetes. Methods: Patients in this randomized, parallel‐group, double‐blind, placebo‐controlled study were drug‐naÏve, aged 43–69 years, with baseline haemoglobin A1c (HbA1c) 5.9–8.1%. Twenty patients received saxagliptin 5 mg once daily; 16 received placebo. Patients were assessed at baseline and week 12 by intravenous hyperglycaemic clamp (0–180 min, fasting state), and intravenous‐oral hyperglycaemic clamp (180–480 min, postprandial state) following oral ingestion of 75 g glucose. Primary and secondary endpoints were percent changes from baseline in insulin secretion during postprandial and fasting states, respectively. Insulin secretion was calculated by C‐peptide deconvolution. Results: After 12 weeks, saxagliptin significantly increased insulin secretion percent change from baseline during the postprandial state by an 18.5% adjusted difference versus placebo (p = 0.04), an improvement associated with increased peak plasma concentrations of intact glucagon‐like peptide‐1 and glucose‐dependent insulinotropic polypeptide. In the fasting state, saxagliptin significantly increased insulin secretion by a 27.9% adjusted difference versus placebo (p = 0.02). Saxagliptin also improved glucagon area under the curve in the postprandial state (adjusted difference −21.8% vs. placebo, p = 0.03). Conclusions: DPP‐4 inhibition with saxagliptin improves pancreatic β ‐cell function in postprandial and fasting states, and decreases postprandial glucagon concentration. Given the magnitude of enhancement of the insulin response in the fasting state, further study into the effect of DPP‐4 inhibition on the β ‐cell is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114 · cited 3×
“Baseline HOMA-2β [27] estimates of βcell function were greater than 100% for both groups (Table 1).”
BackgroundInfluentialCharbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Self-citationVilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528 · cited 14×
“Despite the global increase in β-cell function with saxagliptin treatment that we observed irrespective of the prandial state, postprandial incretin concentrations did respond to saxagliptin (figure 4A, B), with peak levels of intact GLP-1 and GIP increasing several-fold after oral glucose stimulation.”
MethodSelf-citationDeFronzo, R. A., Hissa, M. N., Garber, A. J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., Chen, R. S., & for the Saxagliptin 014 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1984 · Cited by 416
Self-citationBunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Elahi, D. (1996) · Diabetes Care · doi:10.2337/diacare.19.3.278 · Cited by 168 · cited 2×
“Thus, β-cell responses can be measured against identical levels of plasma glucose [20].”
BackgroundMethodEffect of endogenous GLP-1 on insulin secretion in type 2 diabetes
Salehi, M., Aulinger, B., Prigeon, R. L., & D'Alessio, D. A. (2010) · Diabetes · doi:10.2337/db09-1253 · Cited by 124
D'Alessio, D. A., Denney, A. M., Hermiller, L. M., Prigeon, R. L., Martin, J. M., Tharp, W. G., Saylan, M. L., He, Y., Dunning, B. E., Foley, J. E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1135 · Cited by 99 · cited 2×
“Fewer studies have employed stepped clamp [17,19] or ramp [32] procedures to measure insulin response, such as trials with vildagliptin using glucose-insulin infusions.”
Background
Cited by
Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical Applications
Cersosimo, E., Solis-Herrera, C., Trautmann, M., Malloy, J., & Triplitt, C. (2014) · Current Diabetes Reviews · doi:10.2174/1573399810666140214093600 · Cited by 281
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Hædersdal, S., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.12.003 · Cited by 162
Barnett, A. H., Charbonnel, B., Donovan, M., & Fleming, D. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.665046 · Cited by 162
Glucagon secretion from pancreatic α-cells
Briant, L., Salehi, A., Vergari, E., Zhang, Q., & Rorsman, P. (2016) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2016.1156789 · Cited by 109
Dalle, S., Burcelin, R., & Gourdy, P. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2012.11.009 · Cited by 60
Metadata
- Authors
- Henry, R. R., Smith, S. R., Schwartz, S. L., Mudaliar, S. R., Deacon, C. F., Holst, J. J., Duan, R. Y., Chen, R. S., & List, J. F.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-07-26
- Volume
- 13
- Issue
- 9
- Pages
- 850-858
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2116492775
- Cited by
- 49
- References
- 10
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of saxagliptin on β ‐cell stimulation and insulin secretion in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01417.x
- The paper
- Henry, R. R., Smith, S. R., Schwartz, S. L., Mudaliar, S. R., Deacon, C. F., Holst, J. J., Duan, R. Y., Chen, R. S., & List, J. F. (2011). Effects of saxagliptin on β ‐cell stimulation and insulin secretion in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01417.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.